Literature DB >> 17935971

Prostate growth and inflammation.

Alessandro Sciarra1, Gianna Mariotti, Stefano Salciccia, Ana Autran Gomez, Salvatore Monti, Vincenzo Toscano, Franco Di Silverio.   

Abstract

INTRODUCTION: There is emerging evidence that prostatic inflammation may contribute to prostate growth either in terms of hyperplastic (BPH) or neoplastic (PC) changes. Inflammation is thought to incite carcinogenesis by causing cell and genome damage, promoting cellular turnover.
METHODS: We reviewed our personal experience and the international recent literature on the clinical data supporting a role of inflammation on BPH and PC growth and progression.
RESULTS: BPH: Among those patients with self-reported prostatitis, 57% had a history of BPH. MTOPS study showed that men with inflammation had a significantly higher risk of BPH progression and acute urinary retention. We showed that the use of a COX-2 inhibitor in combination with a 5 alpha reductase inhibitor could increase the apoptotic index in BPH tissue. Prostate cancer: A PCR-based analysis of bacterial colonization in PC specimens and normal prostate tissue showed highly suggestive correlation of bacterial colonization and chronic inflammation with a diagnosis of PC. Evidence from genetic studies support the hypothesis that prostate inflammation may be a cause of prostate cancer. De Marzo proposed that proliferative inflammatory atrophy (PIA) is a precursor to PIN and cancer.
CONCLUSION: The concept that inflammation can promote prostate growth either in terms of BPH and PC risk remains highly suggestive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935971     DOI: 10.1016/j.jsbmb.2007.09.013

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  50 in total

Review 1.  High-fat diet, obesity and prostate disease: the ATX-LPA axis?

Authors:  Prakash Kulkarni; Robert H Getzenberg
Journal:  Nat Clin Pract Urol       Date:  2009-02-10

2.  A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate.

Authors:  Salvatore Giordano; Teemu Tolonen; Tuomo Tolonen; Susanna Hirsimäki; Vesa Kataja
Journal:  Int Urol Nephrol       Date:  2009-10-29       Impact factor: 2.370

3.  Characterisation of the prostanoid receptor mediating inhibition of smooth muscle contractility in the rat prostate gland.

Authors:  Slavko Tokanovic; Carl W White; Daniel T Malone; Betty Exintaris; Sabatino Ventura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-02-24       Impact factor: 3.000

4.  The common parasite Toxoplasma gondii induces prostatic inflammation and microglandular hyperplasia in a mouse model.

Authors:  Darrelle L Colinot; Tamila Garbuz; Maarten C Bosland; Liang Wang; Susan E Rice; William J Sullivan; Gustavo Arrizabalaga; Travis J Jerde
Journal:  Prostate       Date:  2017-05-12       Impact factor: 4.104

5.  Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Authors:  D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

6.  Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation.

Authors:  Xiaohai Wang; Wen-Jye Lin; Kouji Izumi; Qi Jiang; Kuo-Pao Lai; Defeng Xu; Lei-Ya Fang; Tianjing Lu; Lei Li; Shujie Xia; Chawnshang Chang
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

7.  Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia?

Authors:  Mario Menschikowski; Albert Hagelgans; Susanne Fuessel; Olga A Mareninova; Volker Neumeister; Manfred P Wirth; Gabriele Siegert
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 8.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

Review 9.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

10.  Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells.

Authors:  Ying Wai Lam; Yong Yuan; Jared Isaac; C V Suresh Babu; Jarek Meller; Shuk-Mei Ho
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.